Objective: We report on differences in atypical antipsychotic adherence after the start of outpatient treatment with atypical antipsychotics in patients receiving routine clinical care, based on whether they had been dispensed antipsychotic medication during the previous 180 days. We hypothesized that prior receipt of an antipsychotic prescription would identify patients with a reduced risk for medication discontinuation, perhaps due to greater experience with illness and/or medication experience.

Methods: De-identified computerized pharmacy records of 406,032 patients from 1157 pharmacies throughout the United States were used to select patients who were dispensed a noninjectable atypical antipsychotic between October 1, 2003, and March 31, 2004. Patients receiving an atypical antipsychotic prescription during this enrollment period were divided into 2 groups. One group consisted of patients to whom antipsychotic medications had been dispensed in the 180-day period prior to the index outpatient fill. The other group was composed of individuals who had not been dispensed a conventional or atypical antipsychotic during this period. Adherence was measured using Kaplan-Meier time-to-discontinuation analysis during a 360-day follow up period after the enrollment date. Discontinuation was defined as being 30 days late for a scheduled refill.

Results: Patients without receipt of an antipsychotic in the 180-day period prior to the index fill composed 32.6% of the total sample of patients (N = 406,432). Women composed 55.2% of the sample; men, 44.8%. The mean age was 43.7 years. In patients previously dispensed an antipsychotic medication, the median time to discontinuation was 125 days, while in patients not previously dispensed an antipsychotic medication, this value was 34 days.

Conclusions: In this analysis of data from pharmacy records, past antipsychotic use appeared to be associated with atypical antipsychotic adherence. Patients without evidence of having been dispensed antipsychotic medication during the 180 days prior to the index antipsychotic prescription appeared to have a high risk for medication discontinuation in the first 30 days after the start of outpatient therapy. This finding suggests that close follow-up during that period in patients who are either new to antipsychotic medication or who are being restarted on an antipsychotic after a prolonged lapse in use may be beneficial.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2007.12.023DOI Listing

Publication Analysis

Top Keywords

atypical antipsychotic
24
antipsychotic medication
20
antipsychotic
17
dispensed antipsychotic
16
antipsychotic adherence
12
patients
12
antipsychotic prescription
12
patients dispensed
12
start outpatient
8
patients receiving
8

Similar Publications

Study Objectives: This study assessed the utilization of potentially inappropriate medications (PIM) including oral sedative-hypnotic and atypical antipsychotic (OSHAA), healthcare resource utilization (HCRU), and costs among elderly individuals with insomnia and in the subpopulation with Alzheimer's Disease (AD) who also had a diagnosis of insomnia.

Methods: Using claims database containing International Classification of Diseases, 10th Revision (ICD-10) codes, the cohort included individuals aged ≥ 65 with incident insomnia (EI, N=152,969) and AD insomnia subpopulation (ADI, N=4,888). Proportion of patients utilizing atypical antipsychotics or oral sedative-hypnotic medications, namely z-drugs, benzodiazepines, doxepin, Dual Orexin Receptor Antagonists (DORAs), and melatonin agonists, were assessed.

View Article and Find Full Text PDF

: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).

View Article and Find Full Text PDF

Aim: Inadequate response to antidepressant therapy (ADT) is common in major depressive disorder (MDD); atypical antipsychotic (AA) adjunctive therapy may be effective for these patients. This study aimed to compare healthcare resource utilization (HRU) and costs between patients initiating the AA cariprazine as their first adjunctive therapy vs those initiating cariprazine subsequently.

Methods: The Merative MarketScan® Commercial Database (January 1, 2015, to June 30, 2021) was used to identify US adults with MDD and ≥1 pharmacy claim for cariprazine adjunctive to ADT in 2018 or after.

View Article and Find Full Text PDF

Introduction: Clozapine is an atypical antipsychotic drug approved for treatment-resistant schizophrenia (TRS). Despite its high efficacy for TRS, clozapine is associated with several serious adverse effects, such as neutropenia and diabetes, so it requires vigilant monitoring. Severe anemia has also been documented as a rare but serious complication with an unclear mechanism.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!